We are committed to growing our already expansive portfolio of over 1,800 brand-name and generic medicines by investing in the future of biosimilar medicines in Canada, with expertise, experience and dedication you can trust.
Manufactured in state-of-the-art facilities and made with the highest quality agents, Teva Canada’s biosimilars deliver safety and efficacy in the treatment of non-Hodgkin’s lymphoma, chronic lymphoblastic leukemia, breast cancer and more.
What is a biologic drug?
To understand what a biosimilar medicine is, it is important to first take a look at biologic drugs.
Biologics are a class of drugs used to treat many kinds of diseases and medical conditions. They are large and complex compounds that come from living organisms or their cells, and include drugs such as insulin, growth hormones and antibodies.
What are biosimilars?
A biosimilar is a drug that is similar, but not identical, to a biologic medicine that Health Canada has already approved for sale. The biologic drug that a biosimilar is modelled after is called its reference biologic drug. The two have no clinically meaningful differences when it comes to safety and efficacy, but they do have some minor differences in the inactive ingredients used in their manufacturing process.
Biosimilars are not generic medicines
While biosimilars are sometimes confused with generics, it is important to remember that biosimilars are NOT generics. Unlike generics, biosimilars are not identical to their reference biologic drugs. Generic drugs are chemical-based, small molecule drugs that are generally easy to copy. Biologics and biosimilars, on the other hand, are large, complex molecules made inside living cells and are harder to copy.
Before they can be approved by Health Canada, biosimilars have to go though an extremely thorough authorization process based on how similar they are to their reference biologic drug. Showing this similarity involves many steps, beginning with structural and functional studies, and moving on to human studies. Teva Canada is committed to making sure that any biosimilar we manufacture is made in state-of-the-art facilities with the highest-quality agents.
Regulatory pathways of originator biologics vs. biosimilars
As biosimilars continue to grow in importance within the Canadian market, they are predicted to contribute to the sustainability of the healthcare system via:
Biosimilars typically cost less than their reference biologics.
Biosimilars introduce competition, which in turn may also help reduce costs.
Improved drug accessibility
Savings from biosimilars could be put towards funding for other much-needed therapeutic areas.
Our well-established and trusted history in making and supplying medications can be seen in our strong product line of 1,800 medicines.
We are committed to building on this history through the investment and development of biosimilars that are comparable in safety, purity and potency.